Dear Editor,The COVID-19 pandemic caused by SARS-CoV-2 has led to acute respiratory distress syndrome(ARDS)with a high rate of death.An excessive inflammatory response,caused by virus infection,is associated with seve...Dear Editor,The COVID-19 pandemic caused by SARS-CoV-2 has led to acute respiratory distress syndrome(ARDS)with a high rate of death.An excessive inflammatory response,caused by virus infection,is associated with severe clinical manifestations that may lead to death of patients.1 Therefore,the blockage of virus replication and suppression of hyper-inflammatory response are beneficial for COVID-19 treatment.However,the drug targeting both virus and hyper-inflammation,as far as we know,is not available yet.展开更多
基金supported by National Key R&D Program of China[2018YFA0107000]National Natural Science Foundation of China Grants(82025014,31900516,8201101103,81870506,and 21701194)+3 种基金Guangzhou Municipal People's Livelihood Science and technology plan[201803010108]Fundamental Research Funds for Central Universities(20lgpy119,19lgpy177)the China Postdoctoral Science Foundation(2019M653170)Shenzhen Key Medical Discipline Construction Fund(SZXK002)and grant from COVID-19 emergency tackling research project of Shandong University(Grant No.2020XGB03 to P.H.W).
文摘Dear Editor,The COVID-19 pandemic caused by SARS-CoV-2 has led to acute respiratory distress syndrome(ARDS)with a high rate of death.An excessive inflammatory response,caused by virus infection,is associated with severe clinical manifestations that may lead to death of patients.1 Therefore,the blockage of virus replication and suppression of hyper-inflammatory response are beneficial for COVID-19 treatment.However,the drug targeting both virus and hyper-inflammation,as far as we know,is not available yet.
